openPR Logo
Press release

Investigation announced for Investors in shares of Amgen Inc. (NASDAQ: AMGN) over potential Wrongdoing

07-01-2022 04:19 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Amgen Inc. (NASDAQ: AMGN) shares over potential wrongdoing at Amgen Inc. was announced.

An investigation on behalf of investors in Amgen Inc. (NASDAQ: AMGN) shares over potential wrongdoing at Amgen Inc. was announced.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Amgen Inc.

Investors who purchased shares of Amgen Inc. (NASDAQ: AMGN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Amgen Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

Thousand Oak, CA based Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Amgen Inc. reported that its annual Total Revenue rose from over $25.42 billion in 2020 to over $25.97 billion in 2021, and that its Net Income declined from over $7.26 billion in 2020 to over $5.89 billion in 2021.
On April 27, 2022, Amgen Inc disclosed in its first quarter 2022 earnings release that "[o]n April 18, 2022, Amgen received a notice of deficiency from the [Internal Revenue Service ('IRS')] for the 2013-2015 period proposing adjustments primarily related to the allocation of profits between certain of the Company's entities in the United States and the U.S. territory of Puerto Rico" which "seeks to increase Amgen's U.S. taxable income for the 2013-2015 period by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest." Amgen Inc also disclosed that the IRS "notice proposes penalties of approximately $2 billion."

Shares of Amgen Inc. (NASDAQ: AMGN) declined $258.39 per share on April 21, 2022, to $231.15 per share on April 28, 2022.

Those who purchased shares of Amgen Inc. (NASDAQ: AMGN) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Amgen Inc. (NASDAQ: AMGN) over potential Wrongdoing here

News-ID: 2668452 • Views: 413

More Releases from Shareholders Foundation

Investigation announced for Investors in certain Waste Management, Inc. (NYSE: W …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Waste Management, Inc. (NYSE: WM) was announced. Investors in certain Waste Management, Inc. (NYSE: WM) Senior Notes, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in certain Waste Management, Inc. (NYSE: WM) Senior Notes follows a lawsuit filed
Lawsuit filed for Investors in shares of Barclays PLC (NYSE: BCS) Investor Alert …
An investor, who purchased shares of Barclays PLC (NYSE: BCS), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Barclays PLC in connection with certain allegedly false and misleading statements. Investors who purchased shares of Barclays PLC (NYSE: BCS), you have certain options and for certain investors are short and strict deadlines running. Deadline: November 22, 2022. NYSE: BCS investors should contact the Shareholders Foundation
Investigation announced for Investors in Torrid Holdings Inc (NYSE: CURV) over p …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Torrid Holdings Inc. Investors who purchased shares of Torrid Holdings Inc (NYSE: CURV) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Torrid Holdings Inc directors breached their fiduciary duties and caused damage to the company and its shareholders. City
Deadline on October 17th coming up in Lawsuit for Investors in Co-Diagnostics, I …
A deadline is coming up on October 17, 2022 in the lawsuit filed for certain investors of Co-Diagnostics, Inc. (NASDAQ: CODX). Investors who purchased shares of Co-Diagnostics, Inc. (NASDAQ: CODX) have certain options and there are strict and short deadlines running. Deadline: October 17, 2022. NASDAQ: CODX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the complaint filed in the U.S. District Court for

All 5 Releases


More Releases for Amgen

Biotechnology Market Set for Rapid Growth| Top Players: Amgen Inc, Amgen Inc, Ce …
Global Biotechnology Market is set to exceed USD 775 billion by 2024; according to a new research report by Global Market Insights. Biopharmacy segment dominated the overall market and accounted for 61.7% revenue share in 2017. Biopharmacy segment is anticipated to grow in forthcoming years due to increasing usage of bio-recombinant proteins in several vaccines to treat numerous diseases. Biopharma companies focus on advancement of personalized medicines that should further
Biotechnology Market Competitive Landscape with Amgen Inc, Amgen Inc, Celgene, M …
The Biotechnology Market to exceed USD 775 billion by 2024 as per a new research report. Favorable government initiative and growing demand for synthetic biology will drive the biotechnology industry growth over the forecast timeframe. Also rising demand for agro-based products should fuel global biotechnology market growth. Decreasing cost of DNA sequencing from last couple of decades owing to the advances in the field of genomics will stimulate the global biotechnology
Gastrointestinal Cancer Drugs, Market: Huge Growth Opportunities by Top Manufact …
The report attempts to offer high-quality and accurate analysis of the global Gastrointestinal Cancer Drugs market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Gastrointestinal Cancer Drugs market that are impacting their business. Readers can become aware of crucial opportunities available in the global Gastrointestinal
Global Erythropoietin Market 2019 - Amgen, Johnson & Johnson, Roche
This new report by Eon Market Research, titled “Global Erythropoietin Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Erythropoietin industry at a global as well as regional and country level. Key facts analyzed in this report include the Erythropoietin market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study of the competitive
Biotechnology Market Competitive Landscape with Amgen Inc, Amgen Inc, Celgene, M …
Biotechnology Market to exceed USD 775 billion by 2024 as per a new research report. Favorable government initiative and growing demand for synthetic biology will drive the biotechnology industry growth over the forecast timeframe. Also rising demand for agro-based products should fuel global biotechnology market growth. Decreasing cost of DNA sequencing from last couple of decades owing to the advances in the field of genomics will stimulate the global biotechnology market. Furthermore,
2018 Biologic Drugs Market Future by Manufacturers- Roche, Abbott Laboratories, …
Download PDF Sample @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1656420 The Global Biologic Drugs Industry Report 2018 is a professional and in-depth study on the current state of the Biologic Drugs Market. Key Companies Analysis- Roche, Abbott Laboratories, Johnson & Johnson, Merck & Co., Pfizer, Amgen, Sanofi, Novartis, Eli Lilly, Amgen Complete report on Biologic Drugs market spread across 94 pages, profiling 10 companies and supported with